Phase 2 Trial of NeuVax Vaccine for HER2-positive DCIS Fully Enrolled, Sellas Announces

Phase 2 Trial of NeuVax Vaccine for HER2-positive DCIS Fully Enrolled, Sellas Announces
The Phase 2 trial evaluating Sellas Life Sciences' cancer vaccine NeuVax as a treatment for women with early stage HER2-positive ductal carcinoma in situ (DCIS), a non-invasive breast cancer, has completed patient enrollment. The vaccine is made of Sellas' nelipepimut-S, the active ingredient that educates the immune system to recognize and mount an attack against the HER2 protein, and the growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF), which increases the amount of tumor killing cells and the vaccine's activity. The 13 women taking part in the VADIS study (NCT02636582) have been assigned to either  NeuVax — meaning a combination of nelipepimut-S and GM-CSF — or to GM-CSF alone, a treatment approved as Leukine (sargramostin). Treatment is being given prior to breast cancer surgery. Those in the vaccine arm will receive a nelipepimut-S injection two weeks before GM-CSF. Patients in the Leukine arm will receive two GM-CSF injections before surgery, given two weeks a
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.